Successful SEC-MALS analysis of proteins and AAVs

ZÁZNAM | Proběhlo Út, 11.7.2023

Případové studie s použitím kolon XBridge Premier BEH SEC v kombinaci s rozptylem světla jako platformového přístupu aplikovaného na tyto různé farmaceutické analyty.

Přejít na webinář

Waters Corporation: Successful SEC-MALS analysis of proteins and AAVs

For therapeutic antibodies and emerging gene-based medicines, light scattering techniques provide multi-attribute quantification (MAQ) and hence play a critical role in product and process development as well as quality control.

Size-exclusion chromatography with multi-angle light scattering (SEC-MALS) is employed throughout the development cycle of the protein therapeutics for bioanalytical characterization.

In addition, SEC-MALS offers a platform method for quantifying multiple quality attributes of AAV-delivered gene therapy products including titer, payload and aggregate content as well as extended biophysical characterization. In the webinar, we share some case studies using XBridge Premier BEH SEC columns combined with light scattering as a platform approach applied to these different pharmaceutical analytes.

Presenter: Leo Liu, Ph.D. (Application Scientist, Waters-Wyatt Technology)

Waters Corporation

Successful SEC-MALS analysis of proteins and AAVs

Mohlo by Vás zajímat

Simultaneous Quantitation and Discovery analysis: Combining targeted and untargeted metabolomics on Orbitrap mass spectrometers

Analysis of Per- and Polyfluoroalkyl Substances (PFAS) in Wastewater

Non-Targeted Screening of Biosolids with the Xevo™ MRT Mass Spectrometer Reveals New Isoforms of PFAS

High Resolution Characterization of Lipid Nanoparticles Using the Xevo™ Charge Detection Mass Spectrometry (CDMS) Instrument - Single Particle Mass Analysis of Intact LNP-mRNA Formulations

Out-of-the-box workflow for PFAS quantitation using a fullscan high-resolution approach with the Orbitrap Exploris EFOX Mass Detector